Best of ASCO - 2014 Annual Meeting

 

Welcome

Non-Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study.

Stephane Chauvie

e19042

A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.

Marco Montillo

TPS7575

A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.

Hui Liu

7557

A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.

Pierluigi Porcu

7551

Ability of routine blood tests (RBTs) in asymptomatic patients (pts) with indolent non-Hodgkin lymphoma (iNHL) to detect relapse or clinically significant disease progression.

Oliver Piercey

e19027

Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).

Akash Mukherjee

7550

ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Peter Hillmen

TPS7572

An objective based model of published treatment options for relapsed or refractory (R/R) peripheral t-cell lymphoma (PTCL): An evidence-based decision-making approach.

Enrica Marchi

e19048

Are double-hit lymphoma patients being adequately evaluated for CNS disease?

Christie Hancock

e19036

Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma.

Erin Dean

7562

Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.

Veronika Bachanova

e19066

Cause-specific mortality in survivors of lymphoplasmacytic lymphoma (LPL) and waldenstrom macroglobulinemia (WM).

Nicole H. Dalal

e19056

Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory DLBCL subjects.

Alexander F. Lovejoy

7546

Checkpoint inhibitor therapy, with and without radiation, in diffuse large B cell lymphoma: A single-center analysis.

Stephanie Yoon

e19059

Clinical characteristics and prognosis of primary breast lymphoma: Cleveland Clinic experience.

Tariq Zuheir Kewan

e19035

Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).

Amy S. Ruppert

7544

Comparison of salvage therapies for relapsed or refractory diffuse large B-cell lymphoma (DLBCL): Network meta-analysis.

Venkata Vosuri

e19037

Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.

Tatyana Feldman

e19060

Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.

John Lin

7561

Disease characteristics of diffuse large B-cell lymphoma predicting relapse after autologous stem cell transplantation.

Daria Gaut

e19030

Distribution and influencing factors of tumor mutational burden in different lymphoma subtypes.

Hui Zhou

e19053

Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic population.

Mohamad Barakat

7535

Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients.

Tong Chen

e19028

Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.

Andreas Viardot

e19041

Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy.

Reza Sirous

7560

Early progression of disease (POD24) as survival predictor in MALT lymphoma.

Annarita Conconi

7548

Efficacy and safety of PEG-rhG-CSF in primary and secondary prevention of chemotherapy-induced neutropenia.

Jun Zhu

e19051

Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).

John G. Gribben

7514

Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.

Yucai Wang

7556

Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: Results from the MAVORIC study.

Larisa J. Geskin

e19031

ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).

Michael Dickinson

TPS7573

Elevated serum lactate in lymphoma: Not always infection.

Sangeetha Gandhi

e19039

ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1.

Stephen Smith

TPS7569

Extranodal (EN) and spleen disease by FDG-PET/CT is associated with early clinical failure in untreated follicular lymphoma (FL).

Frederique St-Pierre

7554

First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study.

Norbert Shmitz

7503

GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkin’s lymphoma.

Senem Ertan-Ahmed

e19065

Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.

Paolo Strati

7545

High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.

Alfadel Alshaibani

e19058

Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report.

Reem Karmali

7542

Impact and influence of PET on imaging related endpoints in patients with Lymphoma using IWG-NHL or Lugano classification.

Manish Sharma

e19061

Impact of absolute lymphocyte count on prognosis of aggressive non-Hodgkin lymphoma.

Anahat Kaur

e19034

Impact on survival of surveillance imaging after first remission in follicular lymphoma.

Jimmy Mao

7536

Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.

Jeremy S. Abramson

7515

Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.

Sirpa Leppä

7553

MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.

David Jacob Andorsky

7513

Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).

Nancy L. Bartlett

7518

Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.

Mohamad Barakat

7549

Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.

Matthew Joshua Frank

7552

NHL and rituximab biosimilar: How have prescribing behaviours changed in EU5 in 15 months?

Alessandra Franceschetti

e19054

Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium.

Jay Y. Spiegel

7517

Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.

Thomas David Rodgers

7547

Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).

Sattva Swarup Neelapu

7555

Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).

Jithma P. Abeykoon

7509

PET/CT alone versus PET/CT and MRI-guided therapy in patients with upper aerodigestive tract natural killer/T-cell lymphoma, nasal type: A prospective study.

Tongyu Lin

7537

Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients (pts) with r/r non-Hodgkin lymphoma.

Allison Claire Rosenthal

e19055

Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

Thomas E. Witzig

7519

Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).

Morton Coleman

e19038

Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).

Stephen Opat

TPS7568

Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).

Avyakta Kallam

e19063

POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.

Herve Tilly

TPS7571

Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.

Catherine Diefenbach

7505

Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Max S. Topp

7558

Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy.

Paolo Strati

7540

Real-world treatment patterns among patients (pts) diagnosed with primary mediastinal large B-cell lymphoma (PMBCL) in the United States (US).

Xiaoqin Yang

e19050

Response to A+CHP by CD30 expression in the ECHELON-2 trial.

Ranjana H. Advani

7538

Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.

Deepa Jagadeesh

7543

Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).

Andrew David Zelenetz

7512

Retrospective analysis of elderly patients with DLBCL: Single center experience with FIL.

Yasir Khan

e19024

Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.

Elly J. Lugtenburg

7507

Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.

Saurabh Zanwar

7559

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL.

Grzegorz S. Nowakowski

7520

Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.

Michael Wang

7516

Sandoz rituximab (GP2013; SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL): Interim safety results of the non-interventional, observational, multicenter, open-label REFLECT study.

Manfred Welslau

e19020

Single-center analysis of post-transplant lymphoproliferative disorder (PTLD) outcomes with Epstein Barr virus (EBV) assessments.

Justin Moyers

e19029

Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).

Rong Tao

7504

Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma.

Jason Westin

7508

Substitution of single dose intravenous methylprednisolone (MP) for oral prednisone (Pred) in RCHOP in intermediate grade non-Hodgkin’s lymphoma (NHL).

Walter Quan

e19019

Survival disparities of diffuse large B-cell lymphoma in a community-based cancer center.

Vinicius Machado Jorge

7541

Survival outcomes in the elderly with limited stage diffuse large B-cell lymphoma treated with chemotherapy: SEER propensity-matched analysis.

Ravi Kaisreddy

e19046

Survival outcomes of patients with peripheral T-cell lymphomas (PTCL) treated with chemotherapy and/or novel agents: The Columbia University experience.

Helen Ma

e19049

SYK inhibition with fostamatinib in Waldenström's macroglobulinemia: In vitro cell based assays.

Vadim Markovtsov

e19047

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).

Jose Caetano Villasboas

TPS7570

The efficacy of ibrutinib-based combination therapy for mantle cell lymphoma: A systematic review.

Prem Thirunagari

e19043

The influence of parvovirus B19 (B19V) on the results of chemotherapy in adult patients with lymphoma.

Tatiana A. Zykova

e19022

Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.

Barbara Pro

7539

TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).

Donald L. Patrick

e19052

Treatment outcomes of HIV patients with non-Hodgkin’s lymphoma treated with standard dose CHOP compared with dose-modified CHOP chemotherapy at the Uganda Cancer Institute.

Alex Bakenga

e19025

Tumor-associated myeloid derived suppressor cells of granulocytic nature as a potential biomarker for prognostication of response in treatment of diffuse large cell lymphoma.

Kalyan Kusum Mukherjee

e19040

Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

Nathan Hale Fowler

7506

ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).

Sattva Swarup Neelapu

TPS7574